An observational study in Bacteremia and Fungemia, sponsored by Accelerate Diagnostics, Inc.. Completed at 14 sites in United States. Per ClinicalTrials.gov, last updated 2017-09-27.
Sponsored by Accelerate Diagnostics, Inc. · Observational
The "Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification \& Antimicrobial Susceptibility Testing" is designed to validate the clinical performance of the Accelerate ID/AST System for positive blood culture identification and susceptibility testing in a clinical setting. The data from this study will be used to support the 510(k) submission for FDA clearance and global registrations of the device intended for in vitro diagnostic use.
The clinical study entitled "Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification \& Antimicrobial Susceptibility Testing" is designed to demonstrate the clinical performance of the Accelerate ID/AST System for positive blood culture identification (ID) and antimicrobial susceptibility testing (AST) in a clinical setting compared to reference results. Approximately 3,000 positive blood culture samples (across all Clinical Sites) will be tested on the investigational device and reference methods. Up to 50% of samples enrolled will be comprised of seeded blood cultures prepared from clinical stock isolates. Quality Control testing will be performed each day of testing. The study population is comprised of left-over clinical specimens that are indicated as positive by blood culture monitoring systems utilized by clinical microbiology laboratories. Positive blood culture samples must be tested on the Accelerate ID/AST System within 8 hours of positivity by the blood culture monitoring system. Testing of clinical samples will continue until the required sample size for each target organism and antimicrobial agent, including sufficient on-scale and resistant strains, are tested across all the sites.
297 studies on the registry are indexed under Bacteremia; 51 are open to participants now.
This study's enrollment of 4,009 is above the median of 300 across 125 observational studies indexed under Bacteremia.
Browse Bacteremia studies →Accelerate Diagnostics, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Clinical specimens that are indicated as positive by blood culture monitoring systems utilized by clinical microbiology laboratories.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Comparison Study - ID Performance
Positive and Negative Percent Agreement with Comparator Method (Vitek2) by Bacterial/Fungal Target
Time frame: Approximately 9 months (including pre-clinical phase)
Comparison Study - AST Performance
Essential and Categorical Agreement with CLSI Frozen Reference Method (BMD) by Antimicrobial
Time frame: Approximately 9 months (including pre-clinical phase)
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Accelerate Diagnostics, Inc.